Investor Presentaiton
Extending the foundations for AFT's future growth
PRESCRIPTION ONLY MEDICINE
KEEP OUT OF REACH OF CHILDREN
maxigesiC IV
Paracetamol 1000 mg and ibuprofen (as sodium dihydrate) 300 mg in
100 mL
Solution For Infusion
Ta
P
MEDICINE
Exigesic
10x100 als 000000000 AF Tosyanditures fur
V
Core Australasian markets supported by new product
launches and consolidation of leadership position across
therapeutic focus areas.
MaxigesicⓇ commercialisation momentum continues
-
Sustained market leadership in Australia
Maxigesic IVⓇ licenses extend including the landmark
licensing deal with Hikma in the US and registrations
now in 29 countries.
Tablets now sold in 46 countries with Switzerland,
Greece and Lithuania added.
Accelerating Asia and E-Commerce
Development portfolio expands with trials for a new
application of Pascomer and ongoing development of
Maxigesic dose forms and NasoSurf
CRYSTAWASH
EXTEI
Sanitising Spr CRYSTAWASH
maxigesiCIV
WASH
TEND
EXTEND
Sanitiser
Foaming
Hand Sanitiser
0:00 17
os
Ladack
AFTpharmaceuticals
99.99
HYLO-
PORTE
HYLO
FRESH
NOVATEARS
TO HAND, PULL HERE
EYE DRC
VITAMIN C
LIPO-SACHETS
VITAMIN C
LIPO-SACHETS
LIPOSHELL
Page 4View entire presentation